1. Hormone Therapy for Prostate Cancer: Exploring Current Controversies
Francesco Montorsi, Richard Berges, Jacques Irani, Claude C. Schulman 
European Urology Supplements 
Volume 8, Issue 9, Pages (September 2009)
DOI: /j.eursup
Copyright © 2009 European Association of Urology Terms and Conditions

2. Fig. 1
The effect of 3 mo versus 8 mo of neoadjuvant androgen deprivation therapy (ADT) prior to conventional-dose radiotherapy (RT) on disease-free survival for low-risk, intermediate-risk, or high-risk localised prostate cancer (PCa) in a Canadian phase 3 trial [20].
NS=not significant.
European Urology Supplements 2009 8, DOI: ( /j.eursup )
Copyright © 2009 European Association of Urology Terms and Conditions

3. Fig. 2
Ten-year follow-up results of the Radiation Therapy Oncology Group (RTOG) trial evaluating long-term (2 yr) adjuvant hormone therapy (LTAD) over short-term (4 mo) adjuvant hormone therapy (STAD) with radiotherapy (RT) in locally advanced prostate cancer [22].
NS=not significant.
European Urology Supplements 2009 8, DOI: ( /j.eursup )
Copyright © 2009 European Association of Urology Terms and Conditions

4. Fig. 3
Overall survival data of the South European Uroncological Group (SEUG) trial comparing intermittent (Int; n=314) with continuous (Cont; n=312) maximal androgen blockade in patients with T3-T4 M0-1 prostate cancer who did not receive previous treatment [32]. Reprinted with permission from Elsevier.
European Urology Supplements 2009 8, DOI: ( /j.eursup )
Copyright © 2009 European Association of Urology Terms and Conditions

5. Fig. 4
Preferred frequency of injections for patients aged ≤70 yr (n=89) or >70 yr (n=111) [40].
European Urology Supplements 2009 8, DOI: ( /j.eursup )
Copyright © 2009 European Association of Urology Terms and Conditions